{ }
Light Horse Therapeutics has entered a strategic collaboration with Novartis, securing a $25 million upfront payment and the potential for up to $1 billion in milestone payments for research, development, and sales. This partnership aims to leverage Light Horse's innovative platform to develop first-in-class therapeutics, particularly targeting challenging oncology areas. The collaboration is expected to accelerate the creation of novel cancer treatments, utilizing advanced genetic screening and proprietary chemical libraries.
Light Horse Therapeutics has launched with a $62-million series A financing and a collaboration with Novartis potentially worth over $1 billion. The San Diego-based biotech employs a "function-first" approach to drug discovery, focusing initially on oncology targets while integrating precision genome editing techniques. The partnership includes a $25-million upfront payment and opportunities for significant R&D and sales milestones.
Trending
Subcategory:
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.